StockIQStockIQ.tech

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis

--

Free AI-powered analysis and research for Ultragenyx Pharmaceutical Inc. stock

Sector: Healthcare

Full RARE report

Ultragenyx Pharmaceutical Inc. (RARE) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze RARE Now β†’

πŸ“° Latest Update

Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...

Ultragenyx Pharmaceutical Inc (RARE) reaffirmed its 2026 total revenue guidance of $730 million to $760 million, driven by growth from established products and the recent FDA approval of two new gene therapies, GENGLYCOS and FAYUVI. The company is projecting full-year GAAP net income profitability in 2027, supported by significant expense reductions and approximately $350 million in non-dilutive capital from the sale of two Priority Review Vouchers. However, RARE is discontinuing its GTX-102 and UX701 programs due to efficacy failures, leading to a 20% workforce reduction.

Read full article β†’

History

People also watch

DHR
Danaher Corporation
--
MCK
McKesson Corporation
--
GILD
Gilead Sciences Inc.
--
LUNG
Pulmonx Corporation
--
CRL
Charles River Laboratories International, Inc.
--